Scinai Immunotherapeutics Ltd

Price Chart

Risk-Adjusted Performance

Scinai Immunotherapeutics Ltd (SCNI) Price Performance

Scinai Immunotherapeutics Ltd (SCNI) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $0.46, down 16.02% from the previous close.

Over the past year, SCNI has traded between a low of $0.46 and a high of $3.25. The stock has lost 81.9% over this period. It is currently 86.0% below its 52-week high.

Scinai Immunotherapeutics Ltd has a market capitalization of $2.32M, with a price-to-earnings ratio of 0.48.

About Scinai Immunotherapeutics Ltd

Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Compare Scinai Immunotherapeutics Ltd

Side-by-side comparison against top Healthcare peers.